How to Value a Stock

Stock valuation is the process of estimating what a company is actually worth — its intrinsic value — and comparing that estimate to the current market price. If your estimate of intrinsic value is materially higher than the price, you may have found an undervalued stock. If it is lower, the stock may be overpriced regardless of how good the business looks.

The three most common approaches to stock valuation are the DCF model (discounted cash flow), comparable multiples analysis (P/E, EV/EBITDA vs. peers), and earnings power value. Each method has strengths and blind spots. A DCF model forces you to project future cash flows explicitly but is sensitive to assumptions about growth and discount rates. Multiples are intuitive but inherit every mispricing in the peer group. The most reliable valuations triangulate across all three.

This guide teaches a practical, assumption-first framework for valuing any stock. You will learn how to reverse-engineer the expectations embedded in the current price, choose the right valuation method for the business type, normalize financial inputs to avoid garbage-in-garbage-out errors, and set margin of safety rules before committing capital.

A stock trading at $85 per share is not an arbitrary number. It is the market's consensus on what the company's future cash flows are worth today, discounted for risk and time. Embedded in that $85 is an assumed revenue growth rate, an assumed operating margin trajectory, an assumed reinvestment rate, and an assumed cost of capital. Change any one of those assumptions and the “right” price changes with it.

This is why starting with a blank DCF is backwards. You are trying to solve for a number that already exists. The smarter move: reverse-engineer the price. Take the current stock price, the company's trailing financials, and a reasonable discount rate. Then ask: what revenue growth rate and what margin level does this price require to be justified? If the answer is 25% annual growth for a company that has never grown faster than 12%, the price is pricing in a miracle. If the answer is 6% growth for a company that has compounded at 14% for a decade, the price might be pricing in a disaster that isn't coming.

Example: Suppose MedDevice Corp (illustrative) trades at $120 per share with 200M diluted shares, $8B in trailing revenue, 18% operating margins, and $1B in net debt. At a 10% discount rate, reverse-engineering the price reveals the market is baking in ~16% annual revenue growth at 22% steady-state margins. The company has grown revenue 9% CAGR over the past 5 years and never posted margins above 19%. (You can measure the historical growth rate on any ticker with our free CAGR calculator.) The price is not “expensive” or “cheap” in the abstract — it is specifically assuming a growth acceleration and margin expansion that the historical record does not support. That is a concrete, testable disagreement, and it is where your edge starts.

There is no single “correct” valuation method. There are three major lenses, each useful in specific contexts and misleading in others. The skill is knowing which lens to pick for the stock in front of you — and how to triangulate when they disagree.

Use DCF for your independent estimate. Use comps as a sanity check. Use earnings power as the floor. If all three disagree violently, you probably don't understand the business well enough to invest. The choice of method should follow from the type of business, not your personal preference.

Theory is worth nothing until you run the numbers. Here is a concrete worked example, followed by an interactive calculator so you can run the same analysis on any stock.

The calculator above does the same math from the worked example, but lets you plug in any stock. Enter the basics, see what the market is pricing in, then adjust the sliders to reflect your own view. The gap between “what the price implies” and “what you believe” is your thesis. If the gap is small, there is no trade. If the gap is large and you have evidence, you might have an edge.

Garbage in, garbage out. Every valuation model — DCF, comps, earnings power — is only as good as the inputs you feed it. And the inputs that most people feed it are wrong, because they use raw trailing numbers without adjusting for distortions. Before you project anything forward, normalize.

The naive inputs produce a stock that looks like it's growing 18% with 22% margins and $3.60 in FCF per share. The normalized inputs reveal an 11% grower with 19% margins and $2.77 in FCF per share. Same company. Same year. Wildly different valuation outputs.

The four normalizations that matter most:

• Cyclicality: Use mid-cycle revenue and margins, not peak or trough. For commodity producers, model at a 10-year average commodity price, not today's spot.
• One-time items: Strip asset sales, restructuring charges, legal settlements, and gain/loss on investments. If a company has a “one-time charge” every quarter, it's not one-time — it's the business.
• Stock-based compensation: SBC is a real cost. Subtract it from free cash flow. Use fully diluted shares in every per-share calculation.
• Capital allocation quality: A company reinvesting at 25% ROIC deserves a higher multiple than one reinvesting at 8% ROIC, even if current earnings are identical.

The most dangerous moment in valuation is when you have a number and a stock you already like. Confirmation bias will find a way to make the model say “buy.” The countermeasure: set your decision rules before you run the final model. Write down — in advance — what margin of safety you require, what position size you'll take at different price levels, and what specific facts would make you sell.

Margin of safety is not optional. Every intrinsic value estimate is wrong. The discount rate is a guess. The terminal growth assumption is a guess. The margin trajectory is a guess. The margin of safety is the cushion that absorbs all of those errors simultaneously. For a high-quality business with predictable cash flows, a 20–25% margin of safety may be sufficient. For a cyclical, capital-intensive, or competitively threatened business, demand 35–50%.

Position sizing follows from conviction, not excitement. A high-conviction idea with a wide margin of safety and a verifiable catalyst warrants 5–8% of a portfolio. An interesting idea with a narrower margin of safety or less clear catalyst is a 2–3% position. An “it might work out” idea is a watchlist entry, not a position.

These are not theoretical risks. They are the specific errors that destroy returns for investors who otherwise do solid fundamental work. Every one of them feels reasonable in the moment. That's what makes them dangerous.

1. Anchoring on a low P/E

A stock trading at 8x earnings is not automatically cheap. It might be 8x peak earnings in a cyclical business, 8x earnings inflated by a one-time asset sale, or 8x earnings that are about to fall 40%. The P/E tells you the price relative to last year's accounting profits. It tells you nothing about whether those profits are sustainable, growing, or about to collapse. Every value trap in history looked cheap on trailing P/E.

2. Using management guidance as your base case

Management teams are paid to be optimistic. They set guidance to a number they're reasonably confident they can beat, then beat it by 2% so the stock pops on the "earnings surprise." If you model management's long-range revenue targets as your base case, you are building a bull case and calling it neutral. Use management guidance as the upper bound of your scenario range, not the midpoint. Your base case should come from industry base rates and your own analysis of the competitive landscape.

3. Ignoring dilution

A company reports $2B in net income. You divide by 500M shares and get $4 EPS. But the company issued 25M shares in stock-based comp this year, 15M in a secondary offering, and has 40M in dilutive options outstanding. The real share count is growing 3–4% a year, meaning your per-share value is shrinking even as total earnings grow. Always use fully diluted shares. And subtract stock-based comp from free cash flow — it is a real cost paid by existing shareholders through dilution.

4. Confusing peak earnings for normal earnings

Commodity producers, homebuilders, semiconductor companies, and shipping firms all have earnings that spike during upcycles and crater during downturns. If you value a copper miner on its earnings when copper is $4.50/lb, you will massively overpay for the stock. The right approach is to normalize — average earnings across a full cycle, or model the company at a mid-cycle commodity price. Ask: what does this company earn in an average year, not what does it earn in the best year?

5. Terminal multiple you can't defend

In a DCF, the terminal value often represents 60–80% of total value. If you slap a 20x exit multiple on year-5 earnings because "the sector trades at 20x," you've just anchored 70% of your valuation to a single assumption you pulled from today's market environment. Today's multiples reflect today's interest rates, today's growth expectations, and today's risk appetite — none of which you can predict five years out. Use a perpetuity growth model as a cross-check, and run your terminal at 2–3 different multiples to see how much it matters.